AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$RMD

Farrell Michael J. sold $1.1M of RMD

Farrell Michael J. (Chairman and CEO) sold 4,991 shares of RESMED INC (RMD) at $222.44 ($1.11M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Farrell Michael J.
Published Sep 10, 2026, 10:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RMD
Bearish
medium confidence
Mentioned
$RMD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RMDBearishLow
01

Why it matters

A $1.1M sale by the CEO may prompt short sellers to add positions, but the amount is not material for a $10B‑plus market cap.

02

Market read

Primary disclosure of an insider sale; modest materiality but relevant for short‑term traders.

03

What to watch

Potential upcoming earnings or strategic announcements that prompted the pre‑planned sale.

Relevance 5/10Novelty 6/10Timing: transaction dated 2026-09-08

Background

Form 4 filing discloses insider trades; investors monitor such filings for signals.

Company-level read

Ticker impact

$RMDBearishMedium confidence
Context

CEO Michael J. Farrell sold 4,991 shares for $1.1M via a 10b5‑1 plan on 2026‑09‑08.

Expected impact

Potential short‑term downward pressure on RMD stock.

Evidence & confidence

The sale size ($1.1M) is modest for a large cap, but the insider's role heightens relevance.

Market effects

Sector

Limited; medical device sector unlikely to be broadly affected.

Regional

None beyond U.S. equity markets.

Global

Low; isolated insider transaction.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Company
    ResMed Inc.

    Medical device manufacturer listed on NYSE under ticker RMD.

  • Executive
    Michael J. Farrell

    Chairman and CEO of ResMed.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RMD insider trading history →

Related articles

SEP 28
$RMDMed

Health Check: No 'Wharfie Time' curse as healthcare stocks kick away from the pack

ASX healthcare stocks, led by CSL (ASX:CSL) and ResMed (ASX:RMD), gained institutional investor interest, with Morgan Stanley noting increased overweight positions. RBC Capital upgraded several healthcare stocks, citing better-than-expected earnings. Healius (ASX:HLS) plans to sell Agilex for $160M to Novotech, addressing balance sheet challenges. Paradigm Biopharmaceuticals (ASX:PAR) delayed its trading resumption to address financial matters.

stockhead.com.au5 min
SEP 16
$RMDMed

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

RBC Capital Markets upgraded five ASX-listed healthcare stocks to outperform, citing positive earnings growth and attractive valuations. CSL (ASX: CSL) was highlighted for market share gains, with a $213 price target. ResMed (ASX: RMD) was noted for capital management, with a $262 target. Ramsay Healthcare (ASX: RHC) was praised for cost control, with a $68 target. Fisher & Paykel (ASX: FPH) showed strong growth, with a $52 target. Nanosonics (ASX: NAN) had mixed results but a $3.75 target.

fool.com.au2 min
SEP 16
$RMDMed

ResMed Shares Jump Following RBC Capital Upgrade to Outperform

ResMed (RMD) stock rose 3% after RBC Capital upgraded it to Outperform, raising the price target to $262. Analyst Craig Wong-Pan cited strong growth in sleep devices, both in the Americas and internationally, and projected high single-digit EPS growth over three years. The FDA's recall of a competing device also boosted sentiment.

tikr.com2 min
SEP 15
$RMDHighAI 8/10

Why is ResMed stock rallying today?

ResMed (RMD) stock rose 2.9% after providing fiscal 2027 guidance, projecting 5%-7% revenue growth and 12%-14% EPS growth. RBC upgraded RMD to Outperform, raising its price target to $262. Despite broader market declines, RMD's positive outlook resonated with investors, addressing concerns about GLP-1 headwinds and competition.

investing.com2 min